SPRB Overview

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.

Wall Street analysts forecast SPRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRB is230.50 USD with a low forecast of 160.00 USD and a high forecast of 283.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Spruce Biosciences, Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Spruce Biosciences, Inc. EPS for the last quarter amounts to -11.28 USD, decreased -73.51

Spruce Biosciences, Inc (SPRB) has 8 emplpoyees as of March 30 2026.

Today SPRB has the market capitalization of 86.49M USD.